What factors influence a patient's intent to get colorectal cancer screening?

March 30, 2017

A patient's confidence in their ability to schedule, plan for and properly conduct their part in colorectal screening methods is a key factor that predicts whether they intend to be tested, according to new research from Penn State College of Medicine. The findings suggest that educating patients could improve screening rates.

Although it's recommended that adults between the ages of 50 and 75 undergo screening for colorectal cancer, only 65 percent of Americans were screened in 2010 according to the most recent data from the Centers for Disease Control and Prevention.

"We all know that screening for colorectal cancer makes a difference, but we're really failing to get people adequately screened for it," said lead researcher Mack T. Ruffin, chair of family and community medicine, Penn State College of Medicine.

To improve screening rates, Ruffin worked with colleagues at the University of Michigan, Ann Arbor, and Michigan State University to understand the factors that influence a patient's intent to be tested. The study included 570 men and women from 15 primary care practices in Detroit between 2012 and 2014. The researchers published their results in the American Journal of Preventive Medicine.

Self-efficacy -- a patient's belief that they can schedule the screening, plan for it and properly conduct their part in it -- emerged as the most important factor.

"If you have high self-efficacy, you're far more likely to intend to get screened," Ruffin said. "It reflects knowledge experience, or understanding of the testing options. If you're not sure how to do the test or get it done, you're less likely to intend on getting it."

A patient's confidence may be particularly important for colorectal cancer screening. Both tests for colorectal cancer -- colonoscopy and stool blood testing -- involve a patient's planning and preparation outside of their doctor's office.

Self-efficacy explained associations between such factors as race, attitudes about the importance of the test, and worries about the test.

One goal of the study was to look at how race is associated with intent to be screened. More than a third of study participants were African-American, making this one of the largest studies to look at colorectal screening intent in this population.

"The African-American population in our study had higher intent to get screening and felt like they were more able to do it than the white population, which is unique for colorectal cancer screening," Ruffin said."

The racial finding is unexplained, and the researchers plan to explore it further.

Another finding was more expected. Compared to men, women were less likely to think they were at risk of colorectal cancer -- a common misconception.

"Women often will say, in focus groups or interviews or surveys, 'It's a man's disease,' when, in fact, it equally impacts men and women," Ruffin said.

This, he explained, could influence how much women know about the tests, which might lower their self-efficacy around screening. Women in the study had lower self-efficacy around colorectal cancer screening than men. Ruffin pointed out that women have more "competing demands" when it comes to staying on top of their health. "They've got to worry about breast cancer, heart disease, ovarian cancer, menopause and getting a Pap smear," he said.

Still, colorectal cancer must be presented as a women's health issue, too, he emphasized.

The findings on perceived risk, self-efficacy, and intent to screen point to the importance of better patient education. "But that takes a lot of time," Ruffin said.

Ruffin and collaborators are working on a way to streamline the decision-making process for colorectal cancer screening with an interactive tool. This could free up time for doctors to explain the tests and answer questions that may hinder patients from actually getting screened.

The new study is part of a larger one on the computerized decision aid. The researchers are investigating whether the tool improves screening rates and why. The tool also helps patients and their doctors decide between colonoscopy and stool blood testing, and the researchers will be looking to see if physicians follow this preference in their recommendations to patients.
-end-
Other researchers on this project were Masahito Jimbo, Ananda Sen, Melissa A. Plegue, Sarah T. Hawley, Mary Rapai, Minling Zhang and Yuhong Zhang, University of Michigan; and Karen Kelly-Blake, Michigan State University. The National Cancer Institute funded this study.

Penn State

Related Colorectal Cancer Articles from Brightsurf:

Colorectal cancer treatment: the winning combinations
Chemotherapy has distressing side effects for patients and increases the risk of developing resistance to the treatment.

A new model to predict survival in colorectal cancer
This signature could be useful in clinical practice, especially for colorectal cancer diagnosis and therapy.

Roadmap to reducing colorectal cancer deaths
The American Gastroenterological Association has outlined a strategy to increase the number of people screened via tests that are more convenient, accurate and less expensive and tailored to people's individual cancer risks.

Study provides new insight on colorectal cancer growth
A new study by researchers at the University of Kentucky identifies a novel function of the enzyme spermine synthase to facilitate colorectal cancer growth.

Researchers ID target for colorectal cancer immunotherapy
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a target for colorectal cancer immunotherapy.

Colorectal cancer partner-in-crime identified
A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target.

Cancer cell reversion may offer a new approach to colorectal cancer treatment
A novel approach to reverse the progression of healthy cells to malignant ones may offer a more effective way to eradicate colorectal cancer cells with far fewer side effects, according to a KAIST research team based in South Korea.

A novel pathway to target colorectal cancer
Survival rates for patients with late-stage colorectal cancer are dismal, and new therapeutic strategies are needed to improve outcomes.

Colorectal cancer rates in Canada
The incidence of colorectal cancer among younger adults increased in recent years in this analysis of data from Canadian national cancer registries that included about 688,000 new colorectal cancers diagnosed over more than 40 years.

Cancer drugs promote stem cell properties of colorectal cancer
Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now discovered that a certain group of cancer drugs (MEK Inhibitors) activates the cancer-promoting Wnt signalling pathway in colorectal cancer cells.

Read More: Colorectal Cancer News and Colorectal Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.